Keyphrases
High Risk
100%
Pediatric
100%
Hematological Malignancies
100%
Graft-versus-host Disease (GvHD)
100%
Young Adult Patients
100%
Nonmyeloablative
100%
Blood or Marrow Transplantation
100%
Haploidentical Transplantation
100%
Post-transplantation Cyclophosphamide (PTCy)
100%
Day Range
50%
Cyclophosphamide
50%
Engraftment
50%
Cumulative Incidence
50%
Myeloablative
50%
Haploidentical
50%
Transplant-related Mortality
50%
Adult Patients
25%
Tacrolimus
25%
Transfusion
25%
Platelets
25%
Neutrophils
25%
Moderate to Severe
25%
Pretransplant
25%
Median Time
25%
Low Intensity
25%
Total Body Irradiation
25%
Immunosuppression
25%
Comorbidity
25%
Disease-specific Mortality
25%
Mycophenolate Mofetil
25%
Organ Dysfunction
25%
Conditioning Regimen
25%
Fludarabine
25%
Event-free Survival
25%
Annualized Relapse Rate
25%
Donor Engraftment
25%
National Institutes of Health Consensus Criteria
25%
Preparative Regimen
25%
Medicine and Dentistry
Pediatrics
100%
Cyclophosphamide
100%
Hematologic Malignancy
100%
Bone Marrow Transplantation
100%
Engraftment
75%
Cumulative Incidence
75%
Chronic Graft Versus Host Disease
50%
Immunosuppressive Treatment
25%
Whole Body Radiation
25%
Neutrophil
25%
Platelet
25%
Graft Versus Host Reaction
25%
Acute Graft Versus Host Disease
25%
Conditioning
25%
Tacrolimus
25%
Fludarabine
25%
Event Free Survival
25%
Mycophenolic Acid
25%
Immunology and Microbiology
Cyclophosphamide
100%
Bone Marrow Transplantation
100%
Engraftment
75%
Chronic Graft Versus Host Disease
50%
Graft-Versus-Host Disease
25%
Neutrophil Granulocyte
25%
Immunosuppression
25%
Acute Graft Versus Host Disease
25%
Platelet
25%
Tacrolimus
25%
Conditioning
25%
Comorbidity
25%
Mycophenolic Acid
25%
Event Free Survival
25%
Agricultural and Biological Sciences
Young Adults
100%
Cyclophosphamide
100%
Bone Marrow
100%
Graft Versus Host Reaction
100%
National Institutes of Health
25%
Neutrophil Granulocyte
25%
Immunosuppression
25%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclophosphamide
100%
Hematologic Malignancy
100%
Chronic Graft Versus Host Disease
50%
Tacrolimus
25%
Comorbidity
25%
Graft Versus Host Reaction
25%
Mycophenolic Acid
25%
Fludarabine
25%
Event Free Survival
25%
Acute Graft Versus Host Disease
25%